Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
RLYB
RLYB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RLYB News
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours
Nov 10 2025
NASDAQ.COM
Rallybio Announces Financial Results for Q3 2025 and Shares Business Developments
Nov 06 2025
Newsfilter
Post-Market Activity: Biotech and Medtech Stocks Surge on Increased Volume and Announcements
Oct 03 2025
NASDAQ.COM
Rallybio Finishes Dosing Initial Group in Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study for RLYB116
Sep 25 2025
Newsfilter
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
Jul 09 2025
Yahoo Finance
Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
Jul 08 2025
Benzinga
Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement
Jul 08 2025
TipRanks
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
Jul 08 2025
Newsfilter
Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug
Jul 08 2025
SeekingAlpha
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
Apr 29 2025
Newsfilter
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Apr 15 2025
Benzinga
Jones Trading Downgrades Rallybio to Hold
Apr 15 2025
Benzinga
Rallybio downgraded to In Line from Outperform at Evercore ISI
Apr 11 2025
Business Insider
This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Apr 09 2025
Benzinga
Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints
Apr 08 2025
Benzinga
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
Apr 08 2025
Newsfilter
Show More News
